Transcatheter Closure of Patent Foramen Ovale: A Single Center Experience

Overview

Journal Open Access Maced J Med Sci

Specialty General Medicine

Date 2016 Dec 29

PMID 28028400

Citations 3

Authors

Ivan Milev

Planinka Zafirovska

Zan Zimbakov

Shpend Idrizi

Vilma Ampova-Sokolov

Emilija Gorgieva

Liljana Ilievska

Goce Tosheski

Nikola Hristov

Ljubica Georgievska-Ismail

Tanja Anguseva

Zan Mitrev

Affiliations

Soon will be listed here.

Abstract

Background: Percutaneous transcatheter closure (PTC) of patent foramen ovale (PFO) is implicated in cryptogenic stroke, transitional ischemic attack (TIA) and treatment of a migraine.

Aim: Our goal was to present our experience in the interventional treatment of PFO, as well as to evaluate the short and mid-term results in patients with closed PFO.

Material And Methods: Transcatheter closure of PFO was performed in 52 patients (67.3% women, mean age 40.7 ± 11.7 years). Patients were interviewed for subjective grading of the intensity of headaches before and after the PFO closure.

Results: During 2 years of follow-up, there was no incidence of new stroke, TIA and/or syncope. Follow-up TCD performed in 35 patients showed complete PFO closure in 20 patients (57.1%). Out of 35 patients, 22 (62.9%) reported having a migraine before the procedure with an intensity of headaches at 8.1 ± 1.9 on a scale from 1 to 10. During 2 years of follow-up, symptoms of a migraine disappeared in 4 (18.2%) and the remaining 18 patients reported the significant decrease in intensity 4.8 ± 2.04 (p = 0.0001). In addition, following PFO closure the incidence of the headaches decreased significantly (p = 0.0001).

Conclusions: Percutaneous transcatheter closure of PFO is a safe and effective procedure showing mid-term relief of neurological symptoms in patients as well as significant reduction of migraine symptoms.

Citing Articles

Morphometric study of fossa ovale in human cadaveric hearts: embryological and clinical relevance.

Kishve P, Motwani R Anat Cell Biol. 2021; 54(1):42-50.

PMID: 33691288 PMC: 8017463. DOI: 10.5115/acb.20.286.

European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions.

Pristipino C, Germonpre P, Toni D, Sievert H, Meier B, DAscenzo F EuroIntervention. 2021; 17(5):e367-e375.

PMID: 33506796 PMC: 9724983. DOI: 10.4244/EIJ-D-20-00785.

The Correlation Between Migraine and Patent Foramen Ovale.

Liu K, Wang B, Hao Y, Song S, Pan M Front Neurol. 2020; 11:543485.

PMID: 33335507 PMC: 7736411. DOI: 10.3389/fneur.2020.543485.

References

Mirzaali M, Dooley M, Wynne D, Cooter N, Lee L, Haworth P . Patent foramen ovale closure following cryptogenic stroke or transient ischaemic attack: Long-term follow-up of 301 cases. Catheter Cardiovasc Interv. 2015; 86(6):1078-84. DOI: 10.1002/ccd.26080. View

Guidetti D, Rota E, Morelli N, Immovilli P . Migraine and stroke: "vascular" comorbidity. Front Neurol. 2014; 5:193. PMC: 4189436. DOI: 10.3389/fneur.2014.00193. View

Nietlispach F, Meier B . Percutaneous closure of patent foramen ovale: safe and effective but underutilized. Expert Rev Cardiovasc Ther. 2015; 13(2):121-3. DOI: 10.1586/14779072.2015.1000305. View

. Late-Breaking Abstracts: 57th Annual Scientific Meeting of the American Headache Society. Headache. 2015; 55 Suppl 5:249-65. DOI: 10.1111/head.12693. View

Mojadidi M, Khessali H, Gevorgyan R, Levinson R, Tobis J . Visual migraine aura with or without headache: association with right to left shunt and assessment following transcutaneous closure. Clin Ophthalmol. 2012; 6:1099-105. PMC: 3413347. DOI: 10.2147/OPTH.S30999. View

Stortecky S, da Costa B, Mattle H, Carroll J, Hornung M, Sievert H . Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis. Eur Heart J. 2014; 36(2):120-8. DOI: 10.1093/eurheartj/ehu292. View

Overell J, Bone I, Lees K . Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology. 2000; 55(8):1172-9. DOI: 10.1212/wnl.55.8.1172. View

Hammerstingl C, Bauriedel B, Stusser C, Momcilovic D, Tuleta I, Nickenig G . Risk and fate of residual interatrial shunting after transcatheter closure of patent foramen ovale: a long term follow up study. Eur J Med Res. 2011; 16(1):13-9. PMC: 3351944. DOI: 10.1186/2047-783x-16-1-13. View

Wahl A, Praz F, Tai T, Findling O, Walpoth N, Nedeltchev K . Improvement of migraine headaches after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism. Heart. 2010; 96(12):967-73. DOI: 10.1136/hrt.2009.181156. View

10.

Tanzi A, Onorato E, Casilli F, Anzola G . Is the search for right-to-left shunt still worthwhile?. Acta Neurol Scand. 2015; 133(4):281-8. DOI: 10.1111/ane.12456. View

11.

Schwedt T, Demaerschalk B, Dodick D . Patent foramen ovale and migraine: a quantitative systematic review. Cephalalgia. 2008; 28(5):531-40. DOI: 10.1111/j.1468-2982.2008.01554.x. View

12.

Rigatelli G, DellAvvocata F, Cardaioli P, Giordan M, Braggion G, Aggio S . Improving migraine by means of primary transcatheter patent foramen ovale closure: long-term follow-up. Am J Cardiovasc Dis. 2012; 2(2):89-95. PMC: 3371619. View

13.

Elmariah S, Furlan A, Reisman M, Burke D, Vardi M, Wimmer N . Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical.... JACC Cardiovasc Interv. 2014; 7(8):913-20. DOI: 10.1016/j.jcin.2014.01.170. View

14.

Davis D, Gregson J, Willeit P, Stephan B, Salman R, Brayne C . Patent foramen ovale, ischemic stroke and migraine: systematic review and stratified meta-analysis of association studies. Neuroepidemiology. 2012; 40(1):56-67. PMC: 3707011. DOI: 10.1159/000341924. View

15.

Seiler C . Patent foramen ovale (PFO): is there life before death in the presence of PFO?. Eur J Clin Invest. 2015; 45(8):875-82. DOI: 10.1111/eci.12469. View

16.

Meschia J, Bushnell C, Boden-Albala B, Braun L, Bravata D, Chaturvedi S . Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45(12):3754-832. PMC: 5020564. DOI: 10.1161/STR.0000000000000046. View

17.

Spencer F, Lopes L, Kennedy S, Guyatt G . Systematic review of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale. BMJ Open. 2014; 4(3):e004282. PMC: 3948581. DOI: 10.1136/bmjopen-2013-004282. View

18.

Fox E, Picard M, Chow C, Levine R, Schwamm L, Kerr A . Interatrial septal mobility predicts larger shunts across patent foramen ovales: an analysis with transmitral Doppler scanning. Am Heart J. 2003; 145(4):730-6. DOI: 10.1067/mhj.2003.5. View

19.

Meier B, Frank B, Wahl A, Diener H . Secondary stroke prevention: patent foramen ovale, aortic plaque, and carotid stenosis. Eur Heart J. 2012; 33(6):705-13, 713a, 713b. PMC: 3303713. DOI: 10.1093/eurheartj/ehr443. View

20.

Van De Bruaene A, Stroobants D, Benit E . Percutaneous closure of inter-atrial communications (atrial septal defect and patent foramen ovale): single-centre experience and mid-term follow-up. Acta Cardiol. 2015; 70(2):133-40. DOI: 10.1080/ac.70.2.3073503. View